Interleukin (IL)-17 is emerging as an important
cytokine in
vaccine-induced protection against
tuberculosis disease in animal models. Here we show that compared to parenteral delivery, BCG delivered mucosally enhances
cytokine production, including
interferon gamma and
IL-17, in the lungs. Furthermore, we find that
cholera toxin, delivered mucosally along with BCG, further enhances
IL-17 production by CD4(+) T cells over mucosal BCG alone both in the lungs and systemically. This boosting effect of CT is also observed using a
vaccine regimen of BCG followed by the candidate
vaccine MVA85A. Using a murine Mycobacterium tuberculosis (M.tb)
aerosol challenge model, we demonstrate the ability of
cholera toxin delivered at the time of a priming BCG vaccination to improve protection against
tuberculosis disease in a manner at least partially dependent on the observed increase in
IL-17. This observed increase in
IL-17 in the lungs has no adverse effect on lung pathology following M.tb challenge, indicating that
IL-17 can safely be boosted in murine lungs in a
vaccine/M.tb challenge setting.